Topical Cyclosporine A 0.05% Eyedrops in the Treatment of Vernal Keratoconjunctivitis - Randomized Placebo-Controlled Trial

Basit Öğe Kaydı
dc.contributor.authorKeklikci, Ugur
dc.contributor.authorDursun, Birgul
dc.contributor.authorCingu, Abdullah Kursat
dc.date.accessioned2024-04-24T17:18:14Z
dc.date.available2024-04-24T17:18:14Z
dc.date.issued2014
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground. Vernal keratoconjunctivitis (VKC) is a chronic, bilateral inflammation of the conjunctiva that mostly affects children and young adult males. Management of VKC is primarily aimed at reducing symptoms and preventing serious vision threatening sequelae. Objectives. To assess the efficacy of topical cyclosporine A (CsA) 0.05% on the signs and symtomps in the management of VKC. Material and Methods. This is a placebo-controlled, randomized prospective study. Sixty-two patients with VKC were included in this study. Patients were randomly assigned (1: 1) to treatment with topical 0.05% CsA eyedrops or a placebo (artificial tears) for a period of 4 weeks, 4 times daily. Ocular signs and symptoms were in all patients scored at entry and at the end of 4 weeks. Results. When pre-treatment mean signs and symptoms scores were compared in both groups, there was no significant difference (p > 0.05). However, mean post-treatment scores as regards signs and symptoms were found to be lower in cyclosporine group than those in placebo group (p < 0.001). No side effects of the treatment with CsA 0.05% eyedrops were observed. Conclusions. It was found that topical CsA 0.05% eyedrops were safe and effective in the treatment of patients with VKCen_US
dc.identifier.doi10.17219/acem/37145
dc.identifier.endpage461en_US
dc.identifier.issn1899-5276
dc.identifier.issn2451-2680
dc.identifier.issue3en_US
dc.identifier.pmid24979519
dc.identifier.scopus2-s2.0-84905680139
dc.identifier.scopusqualityQ1
dc.identifier.startpage455en_US
dc.identifier.urihttps://doi.org/10.17219/acem/37145
dc.identifier.urihttps://hdl.handle.net/11468/18684
dc.identifier.volume23en_US
dc.identifier.wosWOS:000342277100018
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherWroclaw Medical Univen_US
dc.relation.ispartofAdvances in Clinical and Experimental Medicine
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCyclosporineen_US
dc.subjectSignen_US
dc.subjectSymptomen_US
dc.subjectTopicalen_US
dc.subjectVernal Keratoconjunctivitisen_US
dc.titleTopical Cyclosporine A 0.05% Eyedrops in the Treatment of Vernal Keratoconjunctivitis - Randomized Placebo-Controlled Trialen_US
dc.titleTopical Cyclosporine A 0.05% Eyedrops in the Treatment of Vernal Keratoconjunctivitis - Randomized Placebo-Controlled Trial
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu